

## Otitis Media with Effusion in under 12s guideline committee meeting 9

**Date:** 28 October and 16 November 2022

**Location:** Via Zoom

**Minutes:** FINAL

<b>28 October 2022 – Day 1</b>	
<b>Committee members present:</b>	
Veronica Kennedy (Topic Advisor)	Present for items 1 – 10
	Present for items 1 – 10
George Wright	Present for items 1 – 10
Lynsey Causley	Present for items 1 – 10
Alex Bennett	Present for items 1 – 10
Tamsin Brown	Present for items 1 – 10
Stuart Harris	Present for items 1 – 7
Devavrata Joshi	Present for items 1 – 10
Jen Royds	Present for items 1 – 10
Sunil Sharma	Present for items 1 – 10
Katy Mitchell	Present for items 1 – 10
Jill Ross	Present for items 1 – 5
Mitul Patel	Present for items 1 – 5

<b>NICE In attendance:</b>		
Sarah Bartel	Business Manager/ Project Manager	Present for items 1 – 10
Stephen Murphy	Clinical Advisor	Present for items 1 – 10
Aye Paing	Systematic Reviewer	Present for items 1 – 10
Paul Jacklin	Senior Health Economist	Present for items 1 – 10

Alexandra Bonnon	Technical Analyst (Economics)	Present for items 1 – 10
Laura Elliff-O'Shea	Senior Systematic Reviewer	Present for items 1 – 10
Clifford Middleton	Guideline Commissioning Manager	Present for items 1 – 6
Timothy Reeves	Guideline Lead	Present for items 1 – 10
Rachel Connolly	Systematic Reviewer	Present for items 1 – 10
Gareth Haman	Senior Medical Editor	Present for items 1 – 10

<b>Cochrane staff</b>
-----------------------

Caroline Mulvaney	Systematic Reviewer	Present for items 1 – 4
Kevin Galbraith	Systematic Reviewer	Present for items 1 – 4

<b><u>Apologies:</u></b>
--------------------------

John Day	Paediatric Audiologist/audiological scientist
Caroline Jones	Chair

<b>1. Welcome</b>
-------------------

Caroline Jones, Chair was not present at this meeting. Stephen Murphy covered this meeting as the Chair and welcomed the attendees to the 9<sup>th</sup> committee (part 1).

The Chair explained the housekeeping and the meeting etiquette.

<b>2. Introductions, apologies and declarations of interest</b>
---

The Chair asked the attendees to introduce themselves.

Apologies were noted as above.

The Chair asked the committee to review the minutes and the actions and decisions log from the previous meeting and these were approved.

No new declarations of interest were declared.

<b>3. Re-runs of evidence</b>
-------------------------------

Laura Elliff-O'Shea, Senior Systematic Reviewer presented the re-runs of evidence.

The committee discussed the evidence and drafted recommendations.

<b>4. Evidence review 4.3: What is the effectiveness of antibiotics for managing OME with associated hearing loss in children under 12 years?</b>
---

<p>Kevin Galbraith, Cochrane presented evidence review 4.3: What is the effectiveness of antibiotics for managing OME with associated hearing loss in children under 12 years?</p> <p>The committee reviewed and discussed the evidence and drafted the recommendations.</p>
<p><b>5. Evidence review 4.3: What is the effectiveness of antibiotics for managing OME with associated hearing loss in children under 12 years?</b></p>
<p>Timothy Reeves, Guideline Lead covered evidence review presentation of 4.3: What is the effectiveness of antibiotics for managing OME with associated hearing loss in children under 12 years?</p> <p>The committee discussed evidence and agreed changes to the draft recommendations.</p>
<p><b>6. Evidence review 5.3 - What should the follow-up strategy be after surgical treatment for OME-related hearing loss in children under 12 years?</b></p>
<p>Aye Paing, Systematic Reviewer covered evidence review presentation of 5.3 - What should the follow-up strategy be after surgical treatment for OME-related hearing loss in children under 12 years?</p> <p>The committee discussed evidence and agreed changes to the draft recommendations.</p>
<p><b>7. Evidence review 5.3 - What should the follow-up strategy be after surgical treatment for OME-related hearing loss in children under 12 years?</b></p>
<p>Timothy Reeves, Guideline Lead covered evidence review presentation of 5.3 - What should the follow-up strategy be after surgical treatment for OME-related hearing loss in children under 12 years?</p> <p>Timothy Reeves took questions from the group and the committee discussed and agreed evidence and changes to the draft recommendations.</p>
<p><b>8. Health economic model update</b></p>
<p>Paul Jacklin, Senior Health Economist presented the health economic model update.</p> <p>Paul Jacklin took questions from the group.</p>
<p><b>9. Editorial queries</b></p>
<p>Timothy Reeves, Guideline Lead covered editorial queries.</p> <p>Timothy Reeves took questions from the group.</p>
<p><b>10. Any other business</b></p>
<p>Committee members were reminded of the dates for the next meeting.</p>

**Location of next meeting: Wednesday 16 November 2022 via Zoom**

<b>19 November 2022 – Day 2</b>	
<b>Committee members present:</b>	
Caroline Jones (Chair)	Present for items 1 – 8
Veronica Kennedy (Topic Advisor)	Present for items 1 – 8
Lynsey Causley	Present for items 1 – 8
Alex Bennett	Present for items 1 – 8
Tamsin Brown	Present for items 5 – 8
Stuart Harris	Present for items 1 – 8
Devavrata Joshi	Present for items 1 – 8
Jen Royds	Present for items 1 – 6
Katy Mitchell	Present for items 5 – 8
John Day	Present for items 1 – 8

<b>NICE In attendance:</b>		
Sarah Bartel	Business Manager/ Project Manager	Present for items 1 – 8
Stephen Murphy	Clinical Advisor	Present for items 1 – 8
Aye Paing	Systematic Reviewer	Present for items 1 – 8
Paul Jacklin	Senior Health Economist	Present for items 1 – 8
Laura Elliff-O'Shea	Senior Systematic Reviewer	Present for items 1 – 8
Clifford Middleton	Guideline Commissioning Manager	Present for items 7 – 8
Timothy Reeves	Guideline Lead	Present for items 1 – 8
Gareth Haman	Senior Medical Editor	Present for items 1 – 8

<b><u>Apologies:</u></b>	
George Wright (part 2)	Lay Member
Sunil Sharma (part 2)	<b>ENT Surgeon</b> (Paediatric ENT and Otology consultant at Alder Hey Children's Hospital, Liverpool)

<b>1. Welcome</b>
-------------------

<p>Caroline Jones, Chair welcomed the attendees to the 9<sup>th</sup> committee (part 2).</p> <p>The Chair explained the housekeeping and the meeting etiquette.</p>
<p><b>2. Introductions, apologies and declarations of interest</b></p>
<p>The Chair asked the attendees to introduce themselves.</p> <p>Apologies were noted as above.</p> <p>The Chair asked the committee to review the minutes and the actions and decisions log from the previous meeting and these were approved.</p> <p>No new declarations of interest were declared.</p>
<p><b>3. Evidence review 3.1 - What is the progression, resolution and recurrence (natural history) of OME without hearing loss at presentation in children under 12 years?</b></p>
<p>Laura Elliff-O'Shea, Senior Systematic Reviewer presented evidence review 3.1 - What is the progression, resolution and recurrence (natural history) of OME without hearing loss at presentation in children under 12 years?</p> <p>The committee discussed the evidence and drafted recommendations.</p>
<p><b>4. Evidence review 3.1 - What is the progression, resolution and recurrence (natural history) of OME without hearing loss at presentation in children under 12 years?</b></p>
<p>Timothy Reeves, Guideline Lead covered evidence review 3.1 - What is the progression, resolution and recurrence (natural history) of OME without hearing loss at presentation in children under 12 years?</p> <p>The committee reviewed and discussed the evidence and drafted the recommendations.</p>
<p><b>5. Evidence review 3.2 - what is the progression, resolution and recurrence (natural history) of OME with hearing loss at presentation in children under 12 years?</b></p>
<p>Aye Paing, Systematic Reviewer presented evidence review 3.2 - what is the progression, resolution and recurrence (natural history) of OME with hearing loss at presentation in children under 12 years?</p> <p>The committee discussed evidence and agreed changes to the draft recommendations.</p>
<p><b>6. Evidence review 3.2 - what is the progression, resolution and recurrence (natural history) of OME with hearing loss at presentation in children under 12 years?</b></p>
<p>Timothy Reeves, Guideline Lead covered evidence review 3.2 - what is the progression, resolution and recurrence (natural history) of OME with hearing loss at presentation in children under 12 years?</p> <p>The committee discussed evidence and agreed changes to the draft recommendations.</p>

<b>7. Editorial queries</b>
Timothy Reeves, Guideline Lead covered editorial queries and amendments to the draft guideline document were made.
<b>8. Any other business</b>
Committee members were reminded of the dates for the next meeting.

**Location of next meeting: Wednesday 30 November 2022 via Zoom**